On September 12, 2025, we entered into an asset purchase agreement (the “eXIthera Purchase Agreement”) with eXIthera Pharmaceuticals, Inc. (“eXIthera”), to acquire its assets
On December 10, 2025, we entered into the Veralox Purchase Agreement pursuant to which Veralox sold to us all, or substantially all, of its right title and interest in the Veralox Assets
The Company agreed to pay the eXIthera royalties equal to 2 % of annual net sales of the pharmaceutical products containing any compounds that are subject to the eXIthera APA.
The Veralox Assets also include the assignment of an Amended and Restated Exclusive License Agreement by and between Veralox and Old Dominion University, as successor in interest to Eastern Virginia …
The Company entered into an engagement agreement with Wainwright, dated August 14, 2025, pursuant to which Wainwright agreed to act as the exclusive placement agent for the Company
The Company agreed to pay eXIthera 50 % of all royalties received by the Company from the Haisco Licensing Agreement following the potential future commercialization of frunexian by Haisco.
Reciprocal relationship from ORANY graph: Reciprocal relationship from CVKD graph: we will raise sufficient funds to support the planned Phase 3 trial or that the trial design will be accepted by the…
we will raise sufficient funds to support the planned Phase 3 trial or that the trial design will be accepted by the FDA. 18 Manufacturing We do not have a manufacturing infrastructure and do not int…
s, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufactur…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CVKD graph: s, government agencies and other public and private research organizations that conduct research, seek patent protec…
Cadrenal Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CVKD-DEBT-8952
Warrants outstanding: 18571
90%
xbrl warrant detail from xbrl 2025-09-30.
CVKD-DEBT-8953
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
Cadrenal Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cadrenal Therapeutics, Inc..
Cadrenal Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CVKD-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 17 tracked holders.
Cadrenal Therapeutics, Inc. Extended Supply Chain Network
